PMV Pharmaceuticals, Inc.

PMVP

PMV Pharmaceuticals, Inc.

PMVP

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2025-10-23Shares Purchased (TTM):0Shares Sold (TTM):1,500,000

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:34,675,321Shares Outstanding:53,331,766Institutional Ownership Pct.:65.02%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	12	39	38	36	44	51	41	49	49	48	38	52
Restricted Cash Current	-	-	-	-	-	-	-	1	1	1	1	1
Marketable Securities Current	67	54	75	93	98	109	129	134	164	150	165	150
Prepaid Expense And Other Assets Current	2	2	2	3	3	3	6	6	5	4	4	3
Assets Current	81	96	115	132	145	163	176	190	219	202	207	205
Property Plant And Equipment Net	0	0	0	0	0	0	0	10	11	11	11	11
Operating Lease Right Of Use Asset	0	0	1	1	1	1	1	8	8	8	8	9
Marketable Securities Noncurrent	-	0	0	0	6	5	14	15	0	15	26	36
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	82	97	117	134	153	171	191	223	238	237	252	261
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	2	3	3	3	4	7	2	5	1	3	2
Accrued Liabilities Current	8	7	8	9	9	6	7	10	6	10	10	9
Operating Lease Liability Current	0	0	0	0	0	0	0	1	1	1	1	0
Liabilities Current	11	9	11	12	12	10	14	14	11	12	14	11
Operating Lease Liability Noncurrent	0	0	0	1	1	1	1	12	12	12	12	13
Liabilities	11	9	12	13	12	11	15	26	23	24	26	23
Stockholders Equity
Additional Paid In Capital Common Stock	554	552	551	549	548	546	545	543	541	538	535	532
Retained Earnings Accumulated Deficit	-483	-464	-446	-428	-407	-386	-369	-346	-326	-325	-310	-294
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	0	-0
Stockholders Equity	72	88	105	121	141	160	176	198	214	213	226	238
Liabilities And Stockholders Equity	82	97	117	134	153	171	191	223	238	237	252	261
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000
Common Stock Shares Issued	53	53	53	53	53	52	52	52	52	51	51	51
Shares Outstanding	53	53	53	53	53	52	52	52	52	51	51	51

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-21.13%	-14.08%	-20.42%	-	-	-	-	-	-	-	-	-
2025	-0.57%	21.18%	59.68%	-3.45%	2.07%	7.59%	-16.20%	-13.38%	-23.94%	-20.12%	-12.20%	-23.17%
2024	-13.33%	-22.86%	-19.52%	7.53%	2.74%	13.70%	-8.99%	-15.73%	-23.03%	-15.91%	-21.21%	-31.36%
2023	-	-	-	-	-	-	26.32%	63.16%	-10.53%	-8.65%	-12.97%	13.51%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.70	11.14	10.09	10.76	12.52	16.75	12.22	13.98	19.22	16.79	14.78	19.16
Quick Ratio	7.52	10.88	9.89	10.50	12.26	16.43	11.79	13.54	18.77	16.48	14.53	18.92
Working Capital	70.84M	87.19M	103.81M	120.15M	133.70M	153.74M	161.29M	176.06M	207.40M	190.40M	193.38M	194.58M
Leverage & Debt
Debt to Equity	0.15	0.10	0.11	0.11	0.09	0.07	0.09	0.13	0.11	0.11	0.12	0.10
Interest Coverage TTM	-17.78	-15.54	-13.60	-12.46	-10.73	-9.21	-8.02	-6.87	-6.46	-6.52	-7.17	-8.52
Debt Ratio	0.13	0.09	0.10	0.10	0.08	0.06	0.08	0.11	0.10	0.10	0.10	0.09
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.41	-1.47	-1.48	-1.56	-1.55	-1.17	-1.14	-1.00	-0.95	-1.27	-1.44	-1.48
Free Cash Flow Per Share TTM	-1.31	-1.41	-1.40	-1.04	-1.00	-1.03	-1.01	-0.92	-0.90	-1.13	-1.18	-1.25
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-6.99%	28.70%	32.42%	60.70%	65.45%	-6.49%	-14.87%	-29.06%	-34.07%	-12.04%	-5.94%	0.30%
EPS Growth (1Y)	-9.39%	25.37%	29.99%	56.40%	63.76%	-7.40%	-20.75%	-32.54%	-41.33%	-21.74%	-10.68%	-6.70%
Valuation Metrics
P/E TTM	-0.95	-0.84	-0.84	-0.90	-0.68	-0.93	-1.33	-1.49	-1.71	-1.34	-2.16	-4.15
P/B TTM	1.00	0.75	0.63	0.61	0.39	0.35	0.44	0.39	0.39	0.41	0.66	1.27
Market Cap	71.54M	66.13M	65.68M	74.19M	55.13M	56.63M	77.88M	76.85M	83.40M	87.46M	148.85M	301.15M
Enterprise Value	59.07M	27.00M	27.69M	37.85M	11.00M	5.29M	37.01M	28.04M	34.87M	39.80M	111.14M	249.09M
Calculated Values
Free Cash Flow TTM	-69.87M	-75.02M	-73.61M	-54.85M	-51.87M	-53.43M	-51.94M	-47.50M	-46.37M	-58.23M	-56.62M	-61.30M
Net Debt	-12.47M	-39.13M	-37.98M	-36.34M	-44.13M	-51.34M	-40.88M	-48.81M	-48.53M	-47.65M	-37.71M	-52.06M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-10-23Sale

Owner: Orbimed, Capital Gp V Llc…

Title: -

Shares: 1,000,000

Price/Share: $1.52

Value: $1,520,000.00

Shares Owned: 4,975,291

Relationship: TenPercentOwner

Ownership: Indirect

2025-09-10Sale

Owner: Orbimed, Advisors Llc, Or…

Title: -

Shares: 500,000

Price/Share: $1.80

Value: $900,000.00

Shares Owned: 5,975,291

Relationship: TenPercentOwner

Ownership: Indirect

2025-07-01Sale

Owner: Mack, David Henry

Title: President and CEO

Shares: 58,411

Price/Share: $1.06

Value: $61,915.66

Shares Owned: 536,133

Relationship: Director,Officer

Ownership: Direct

2025-07-01Sale

Owner: Jalota, Deepika

Title: Chief Development Officer

Shares: 33,065

Price/Share: $1.06

Value: $35,048.90

Shares Owned: 89,959

Relationship: Officer

Ownership: Direct

2025-07-01Sale

Owner: Ticktin, Robert

Title: General Counsel & COO

Shares: 23,151

Price/Share: $1.06

Value: $24,540.06

Shares Owned: 98,695

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-10-23	Orbimed, Capital Gp V Llc…	TenPercentOwner	-	Indirect	Sale	1,000,000	1.52	$1,520,000.00	4,975,291	4
2025-09-10	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	500,000	1.80	$900,000.00	5,975,291	4
2025-07-01	Mack, David Henry	Director,Officer	President and CEO	Direct	Sale	58,411	1.06	$61,915.66	536,133	4
2025-07-01	Jalota, Deepika	Officer	Chief Development Officer	Direct	Sale	33,065	1.06	$35,048.90	89,959	4
2025-07-01	Ticktin, Robert	Officer	General Counsel & COO	Direct	Sale	23,151	1.06	$24,540.06	98,695	4
2025-07-01	Carulli, Michael	Officer	Chief Financial Officer	Direct	Sale	28,249	1.06	$29,943.94	60,146	4
2024-09-11	Carulli, Michael	Officer	Chief Financial Officer	Direct	Sale	2,891	1.50	$4,336.50	88,395	4
2024-09-11	Jalota, Deepika	Officer	Chief Development Officer	Direct	Sale	7,218	1.50	$10,827.00	118,283	4
2023-11-22	Orbimed, Genesis Gp Llc, …	TenPercentOwner	-	Indirect	Sale	87,786	2.23	$195,762.78	0	4
2023-09-15	Alland, Leila	Officer	Chief Medical Officer	Direct	Sale	6,291	6.62	$41,646.42	45,909	4
2023-09-15	Jalota, Deepika	Officer	Chief Development Officer	Direct	Sale	4,104	6.62	$27,168.48	29,946	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

65.02%

Inst. Shares: 34,675,321

Shares Outstanding: 53,331,766

2025-12-31

67.19%

Inst. Shares: 35,301,916

Shares Outstanding: 52,541,613

2025-09-30

66.67%

Inst. Shares: 35,330,537

Shares Outstanding: 52,993,238

2025-06-30

62.61%

Inst. Shares: 32,564,681

Shares Outstanding: 52,010,827

2025-03-31

67.77%

Inst. Shares: 35,209,473

Shares Outstanding: 51,952,062

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	34,675,321	53,331,766	65.02%
2025-12-31	35,301,916	52,541,613	67.19%
2025-09-30	35,330,537	52,993,238	66.67%
2025-06-30	32,564,681	52,010,827	62.61%
2025-03-31	35,209,473	51,952,062	67.77%
2024-12-31	36,601,224	51,578,807	70.96%
2024-09-30	36,569,608	51,574,027	70.91%
2024-06-30	37,583,317	51,478,751	73.01%
2024-03-31	39,918,821	51,445,862	77.59%
2023-12-31	44,968,207	48,014,645	93.66%
2023-09-30	53,604,033	49,047,296	109.29%
2023-06-30	48,115,064	45,813,132	105.02%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

PMV Pharmaceuticals, Inc. (PMVP) — SEC Financial Statements & Analysis

PMV Pharmaceuticals, Inc. (PMVP) is a pharmaceutical preparations company, incorporated in DE. PMV Pharmaceuticals, Inc. trades on Nasdaq as: PMVP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), PMV Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of 0.15x, a Price-to-Book (P/B) ratio of 1.00x (TTM), at a market cap of $71.54M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.15x
P/B TTM: 1.00x
Market Cap: $71.54M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is PMV Pharmaceuticals, Inc. in?

PMV Pharmaceuticals, Inc. (PMVP) operates in the Pharmaceutical Preparations industry.

What is PMVP's market cap?

PMV Pharmaceuticals, Inc. (PMVP) has a market capitalization of $71.54M as of 2026-06-30.

What exchange does PMVP trade on?

PMV Pharmaceuticals, Inc. (PMVP) trades on the Nasdaq.

Where is PMV Pharmaceuticals, Inc. incorporated?

PMV Pharmaceuticals, Inc. is incorporated in DE.